1. Home
  2. SCLX vs SACH Comparison

SCLX vs SACH Comparison

Compare SCLX & SACH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scilex Holding Company

SCLX

Scilex Holding Company

HOLD

Current Price

$6.48

Market Cap

48.5M

Sector

Health Care

ML Signal

HOLD

Logo Sachem Capital Corp.

SACH

Sachem Capital Corp.

HOLD

Current Price

$1.03

Market Cap

46.9M

Sector

Real Estate

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCLX
SACH
Founded
2011
2010
Country
United States
United States
Employees
34
27
Industry
Biotechnology: Pharmaceutical Preparations
Real Estate Investment Trusts
Sector
Health Care
Real Estate
Exchange
Nasdaq
Nasdaq
Market Cap
48.5M
46.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SCLX
SACH
Price
$6.48
$1.03
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$2.00
AVG Volume (30 Days)
92.4K
121.0K
Earning Date
04-10-2026
05-06-2026
Dividend Yield
N/A
19.23%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$122.52
$145.00
Revenue Next Year
$186.30
$6.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.09
$0.80
52 Week High
$34.27
$1.35

Technical Indicators

Market Signals
Indicator
SCLX
SACH
Relative Strength Index (RSI) 39.05 44.56
Support Level $6.20 $0.99
Resistance Level $8.18 $1.12
Average True Range (ATR) 1.38 0.03
MACD -0.32 -0.00
Stochastic Oscillator 1.16 12.50

Price Performance

Historical Comparison
SCLX
SACH

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

About SACH Sachem Capital Corp.

Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns the majority of its revenue through Interest income from loans.

Share on Social Networks: